Presentation is loading. Please wait.

Presentation is loading. Please wait.

An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes  Shannon R. Joseph,

Similar presentations


Presentation on theme: "An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes  Shannon R. Joseph,"— Presentation transcript:

1 An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes  Shannon R. Joseph, Daniel Gaffney, Rachael Barry, Lingbo Hu, Blerida Banushi, James W. Wells, Duncan Lambie, Geoffrey Strutton, Sandro V. Porceddu, Bryan Burmeister, Graham R. Leggatt, Helmut Schaider, Riccardo Dolcetti, Ian H. Frazer, Nicholas A. Saunders, Matthew Foote, H. Peter Soyer, Fiona Simpson  Journal of Investigative Dermatology  Volume 139, Issue 1, Pages (January 2019) DOI: /j.jid Copyright © 2018 The Authors Terms and Conditions

2 Figure 1 Comparison between conventional pathology imaging and confocal imaging of human tissue samples. (a) Comparison of H&E staining and immunofluorescent labeling by confocal microscopy (tile scan) of an invasive SCC. Nuclear disorganization and invasion can be seen clearly in the confocal image where nuclei (DAPI, blue) corresponded to dysplasia seen by H&E. Scale bars = 200 μm. (b) Dysplastic cells within SCC AC3P and DP5 samples overexpressed EGFR. The top rows show H&E staining of 4-μm sections from patient tumors. Original magnification ×4. Scale bars = 200 μm. The images in the middle row show magnification of the regions indicated by white boxes in the panels above. Original magnification ×25. The bottom row shows successive sections of SCC AC3P and SCC DP5 fluorescently labeled with anti-EGFR (anti-mouse Alexa488 secondary, green) and DAPI (blue). Scale bars = 50 μm. H&E, hematoxylin and eosin; SCC, squamous cell carcinoma. Journal of Investigative Dermatology  , DOI: ( /j.jid ) Copyright © 2018 The Authors Terms and Conditions

3 Figure 2 Ligand-induced EGFR endocytosis is dysregulated in advanced SCC. (a) EGF-Alexa488 (green) uptake distribution in tumor (AC3P) SCC after 15 minutes and 30 minutes of stimulation. Magnification of boxed region shown in insert. Uptake of EGF is observed as punctate fluorescence. Scale bars = 20 μm. (b) EGF-Alexa488 (green) uptake distribution in tumor (DP5). Plasma membrane binding of EGF-Alexa488 is observed, but there is little internalization. Image after 30 minutes EGF-Alexa488 incubation in matched normal epithelial tissue is also shown. Scale bars = 20 μm. (c) Super-resolution microscopy of human SCC in which EGFR does not undergo normal ligand-induced internalization (top: dysregulated, SCC DP5) or retains ligand-induced internalization (bottom: internalizing, SCC AC3P). Different distributions of EGF-Alexa488 between the two samples are observed. Blue dotted lines indicate nucleus. Scale bars = 5 μm. min, minute; SCC, squamous cell carcinoma. Journal of Investigative Dermatology  , DOI: ( /j.jid ) Copyright © 2018 The Authors Terms and Conditions

4 Figure 3 EGF ligand uptake can be analyzed in ex vivo tumors. In all images, nuclei are stained with DAPI (blue). (a) Post-fixation labeling of EGFR (31G7, anti-mouse Alexa594; red) co-localizes with EGF-Alexa488 ligand uptake (30 minutes; green, pre-fixation) in dysregulated lesion. (b) Pretreatment of dysregulated lesion with cetuximab before EGF-Alexa488 (green) addition blocks EGF binding. Post-fixation labeling of cetuximab, anti-human Alexa594 secondary (red). (c) EGF-Alexa488 (green) and DEAE-dextran-Alexa555(red) uptake after 30 minutes of incubation in internalizing (left) or endocytically dysregulated lesions (right). Arrowheads indicate co-localization. (d) EEA1 (anti-rabbit Alexa594, red) and EGF-Alexa488 (green, 30-minute uptake) in internalizing (left) and endocytically dysregulated patient lesions (right). Arrowheads indicate co-localization. (e) Clathrin (anti-mouse Alexa594, red) and EGF-Alexa488 (green, 15-minute uptake) in internalizing (left) and dysregulated patient lesion (right). Scale bars = 20 μm. Journal of Investigative Dermatology  , DOI: ( /j.jid ) Copyright © 2018 The Authors Terms and Conditions

5 Figure 4 Pattern of EGF-Alexa488 uptake in the basal layers and at the leading edges in early SCC lesions. After EGF-Alexa488 incubation, various EGF ligand localization subtype patterns were seen in actinic keratosis, intraepidermal carcinoma, and cutaneous SCC. In some lesions, EGFR was internalized in response to EGF-Alexa488 ligand stimulation (internalizing: lesions 18, 11, and 8), whereas in others, no ligand-induced receptor-mediated endocytosis occurred (dysregulated: lesions 3, 7, and 20). In some lesions EGF-Alexa488 was polarized to leading edges of SCC, and in some it was not. The illustration on the right summarizes the EGF ligand localization pattern subtype. Lesion data are summarized in Supplementary Table S3. Scale bars = 20 μm. SCC, squamous cell carcinoma. Journal of Investigative Dermatology  , DOI: ( /j.jid ) Copyright © 2018 The Authors Terms and Conditions


Download ppt "An Ex Vivo Human Tumor Assay Shows Distinct Patterns of EGFR Trafficking in Squamous Cell Carcinoma Correlating to Therapeutic Outcomes  Shannon R. Joseph,"

Similar presentations


Ads by Google